All News
NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19
NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences.
Read Article
Combo Anti-Spike Protein Antibody for Mild to Moderate COVID-19
JAMA has published the BLAZE-1 study, showing significant SARS-CoV-2 viral load reduction at day 11 and less COVID-19 progression when combination anti-spike monoclonal antibody therapy (bamlanivimab and etesevimab) was given to mild to moderate, non-hospitalized COVID-19 patients.
Read Article
Mortality Risk in Rheumatoid Lung Patients
A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks.
Read on: https://t.co/RJxDB8tiRu https://t.co/daZppFnteu
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis RCTs of Antidepressants in painful conditions (LBP, sciatica, hip/knee OA) shows SNRIs (Cymbalta, Savella, Effexor etc) have a small & not clinically important for effect on back pain. A clinically important effect on OA cannot be excluded https://t.co/lGqeEHtbnK https://t.co/wcta0VVSqp
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Smoking and RA: The dastardly, nastardly facts of smoking and RA
https://t.co/H4jeFIXeGq https://t.co/xWxjzGZWQq
Links:
Dr. John Cush RheumNow ( View Tweet)
In the UK, NICE has recommending ed (to NHS) that filgotinib (Jyseleca) be approved for use in moderate to severe active rheumatoid arthritis (RA).https://t.co/g5zLwIa3MK
Links:
Dr. John Cush RheumNow ( View Tweet)
Don’t hold Benlysta for the COVID19 vaccine!
Previous studies have shown that SLE pts on Benlysta (belimumab) still have good antibody response to vaccinations (including Prevnar14, PPSV23, flu and tetanus vaccines).
@RheumNow https://t.co/4rFdcIKjkT
k dao KDAO2011 ( View Tweet)
Canadian lupus cohort of 560 SLE pts without myositis at baseline. Over time, only 5 pts developed myositis (after mean 8.5 yrs). Incidence = 1.05 per 1000 PYs. Arthritis, Raynauds, -Sm Abs were common, but only non-Whites had increased risk of myositis. https://t.co/fzWhUADjMz
Links:
Dr. John Cush RheumNow ( View Tweet)
NEW QD Clinic
Differential Dx Myalgias & Arthralgias
https://t.co/ozawoe6RMO
Links:
Dr. John Cush RheumNow ( View Tweet)
Denosumab inhibiting osteolysis? 22 pts undergoing revision THR surgery for osteolysis, 10 Rx w/ denosumab had 83% fewer osteoclasts @ osteolysis membrane–bone interface. Proof concept: DEN may have osteoclast effects at implant interface https://t.co/dJ06rk0SR3
Links:
Dr. John Cush RheumNow ( View Tweet)
Ehlers-Danlos Syndrome pts have higher association with GI conditions (IBS, etc OR =3.57), POTS & Autonomic dysfunction (OR=4.4), food allergy (OR= 3.9), CV complications (OR 6.1; MV dx, aortic aneurysm), longer hospitalizations (OR= 1.76) https://t.co/noobvrx0cQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Though provoking piece by Dr. Len Calabrese in Healio,He references Drs. Schett and Scher writing in Nature Reviews Rheumatology on KOLs. Both articles are about reflection on what we do, how we do it, what motivates us. Good Reads https://t.co/HDlFRVJq1a https://t.co/CtqqiZuxwo
Dr. John Cush RheumNow ( View Tweet)
Swedish Armed Forces study suggests the least fit are at greatest risk for developing psoriasis later inlife. From 1968 -2005 1,886,542 military recruits were followed mean 31 yrs. Low CV fitness showed higher rate of psoriasis (HR 1.35) and PsA (HR 1.44) https://t.co/52zTjMM24y
Links:
Dr. John Cush RheumNow ( View Tweet)
Factors Predictive of SLE Flare After HCQ Taper/Discontinuation
The benefits of hydroxychloroquine in lupus are many, but what if you were to withdraw HCQ?
Read more: https://t.co/r5iDXBEuQP https://t.co/LImqA9y8Dn
Links:
Dr. John Cush RheumNow ( View Tweet)
Epidemiologic study of #SLE from CDC & lupus registries estimates there are 204,295 SLE pts in USA (2018). Prevalence=72.8 SLE/100,000 and is 9 X higher in females than males (129 vs 14.6/100,000), especially among Ame Indians/Alaska Natives, Black females https://t.co/5yHVQ9UqZ4
Links:
Dr. John Cush RheumNow ( View Tweet)
My note to the FDA staff: https://t.co/n2Pr2Kzrre
Dr. Janet Woodcock DrWoodcockFDA ( View Tweet)
Toci led to poorer outcomes in this study. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ https://t.co/95zaq2CEUU
Dr Philip Robinson philipcrobinson ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz - Plasmablasts may be a useful biomarker; but is not generally available in clinical labs (must be done on fresh whole blood) @UTSWIMchief https://t.co/GlEKw0KD3O
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz common lab findings: hypergammaglobulinemia is common but elevated ESR/CRP are not. Most have elevated IgG4 serum levels @UTSWIMchief https://t.co/wR5FEqZTsX
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz commonly presents as major salivary and lacrimal gland enlargement, orbital disease, autoimmune pancreatitis, retroperitoneal (mass) fibrosis or tubulointerstitial nephritis. @UTSWIMchief
Dr. John Cush RheumNow ( View Tweet)